... oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Patients and Methods: Patients with recurrent ovarian cancer and prior treatment with platinum- and taxane-based chemotherapy were included. Treatment consisted of bevacizumab 10 mg/kg intravenously every 2 weeks plus...

... in Japan to evaluate the efficacy and tolerability of weekly paclitaxel followed by fluorouracil, epirubicin, and cyclophosphamide (FEC) as neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC). Methods: Patients with clinical stage IIIA–IIIB breast cancer received NAC consisting of 12...

...Hiltje de Graaf; Pax H.B. Willemse; Barbara Bong; Henk Piersma; Tonnis Tjabbes; Henk van Veelen; Jules L.L.M. Coenen; Elisabeth G.E. de Vries The effects of granulocyte colony-stimulating factor (G-CSF) on total dose and dose intensity of standard oral adjuvant CMF (cyclophosphamide, methotrexate...

... Methotrexate Cyclophosphamide ONCOLOGY Original Paper Oncology 1996;53:73-78 Liider M. Felsa c Carsten Bokemeyerb Jutta van Rheeb Hans-Joachim Schmollb Hilmar Stolte3 Division of Nephrology, Department of Hematology and Oncology, Medical School Hannover, and Society for Science and Technology Transfer (GWT...

...M. Soukop This paper describes the only published study to date which prospectively evaluates the efficacy of a 5-HT3 receptor antagonist over repeated courses of cyclophosphamide chemotherapy. The combination of ondansetron and dexa-methasone was significantly superior to metoclopramide...

... with cyclophosphamide and doxorubicin in patients with metastatic breast cancer. Of 62 evaluable patients, 31 received UFT® (350 mg/m 2 /day orally x 14 days), doxorubicin (50 mg/m 2 intravenously [IV] day 1) and cyclophosphamide (500 mg/m 2 IV day 1). The other 31 patients received 5-FU (500 mg/m 2 IV days 1 and 8...

...A. Stewart Cyclophosphamide induces moderate to severe emesis. The severity of emesis is dependent on the dose of cyclophosphamide and on the addition of other cytotoxic drugs. A review of the literature dividing studies according to the dose of cyclophosphamide and the specific cytotoxic...

... cyclophosphamide-containing chemotherapy. A total of 406 patients were randomised to receive ondansetron 8 mg p.o. (198 patients) or ondansetron suppository (208 patients) medication in a double-blind, double-dummy trial. The primary efficacy analysis revealed that ondansetron provided good anti-emetic control...

...Edward V. Hannigan; Stephanie Green; David S. Alberts; Robert O’Toole; Earl Surwit Cisplatin combined with cyclophosphamide has been considered a very active treatment for advanced ovarian cancer. Unfortunately, cisplatin is associated with dose-limiting neurotoxicity, as well as possible...

...Yoshinori Ueno; Yutaka Kohgo; Sumio Sakamaki; Yoshinori Itoh; Minoru Takahashi; Yasuo Hirayama; Yoshiro Niitsu The effect of combination immunochemotherapy using interleukin-2 (IL-2), PSK and cyclophosphamide (CY) was evaluated in a pulmonary metastasis model in BDFi mice. B-16 melanoma cells were...

... schedules of ondansetron and granisetron in the control of prolonged emesis after cyclophosphamide-containing chemotherapy (48% CMF, 35% EC) for breast cancer. A total of 514 patients were recruited. Of the 488 patients included in the intent-to-treat analyses, 167 were randomised to group A [8 mg...

... stages III and IV Chemotherapy Cyclophosphamide Doxorubicin Adriamycin Cisplatin Laparotomy, second-look Second-effort surgery Oncology 1991 ;48:7 12 « 1991 S. Karger AG. Basel 0030 2414 91 «4SI 0007 S 2.75 0 Chemotherapy (CAP) for the Treatment of Advanced Ovarian Cancer and Second-Effort...

...K. Kolarić; Z. Mechl On the basis of results obtained with oral idarubicin administration in breast cancer, which have shown an established antitumor activity in approximately 28% of cases, this compound was combined with cyclophosphamide (also given orally) in postmenopausal patients...

... collected over a 5-day period following cyclophosphamide-based chemotherapy given on an outpatient basis for the treatment of breast cancer. Patients received an intravenous dose of 16 mg dexamethasone with either 8 mg ondansetron or 60 mg metoclopramide intravenously before chemotherapy followed by oral...

...M. Clavel; M. Soukop; Y.L.A. Greenstreet Cyclophosphamide-based chemotherapy is often given to patients for the treatment of breast cancer. This chemotherapy can induce severe nausea and vomiting in these patients, which can adversely affect their quality of life, especially as these regimens...

...W.R. Bezwoda; R. Dansey; L. Seymour Seventy-five patients with stage 4 breast cancer were treated with a first-line chemotherapy regimen consisting of cyclophosphamide 600 mg/m 2 , mitoxantrone 12 mg/m 2 , and vincristine 1.4 mg/m 2 (CNV). Objective response was seen in 61/75 (81%) with 17/75 (23...

... included the following drugs in various combinations: cyclophosphamide, adriamycin, fluorouracil, carboplatin and etoposide (VP-16). Complete control of emesis was achieved in a third of the 39 patients. There was no statistically significant difference among the dose levels with regard to the patient’s...

...Fadi Estephan; Vicente Valero; Francisco J. Esteva; Jaime A. Mejia; Debra K. Frye; Nuhad K. Ibrahim Background: A phase I study was initiated to determine the maximum tolerated dose (MTD) of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic breast carcinoma...

...Delvyn C. Case Jr.a.; Marjorie Boyd; Daniel M. Hayes; Brian M. Dorsk Twenty patients with stage III and IV diffuse well-differentiated lymphocytic lymphoma were treated with combination chemotherapy consisting of BCNU, cyclophosphamide, vincristine, melphalan and prednisone (M-2). Treatment...

... the CMF (cyclophosphamide, methotrexate and 5-fluorouracil) combination chemotherapy. The MCP and DXM dosage were: 2 × 2 mg/kg and 2 × 0.2 mg/kg, respectively. In 41 % of eighty evaluable courses, nausea and vomiting were eliminated altogether. The common side effects were: drowsiness, restlessness...